Ventyx Biosciences — Investor Presentation (March 2022)
36 slides from Ventyx Biosciences's investor presentation, Mar 15, 2022
Slide 1: Corporate Presentation First Quarter 2022
Exhibit 99.1 CORPORATE PRESENTATION FIRST QUARTER 2022
Slide 2: Forward Looking Statements
Forward Looking Statements Ventyx cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on Ventyx’s current beliefs and expectations. Such forward-looking statements include, but are not
Slide 3: Introduction & Pipeline
INTRODUCTION & PIPELINE VTX958 | TYK2 Inhibitor | Phase 1 VTX002 | S1P1R Modulator | Phase 2 VTX2735 | Peripheral NLRP3 Inhibitor | Phase 1 CNS NLRP3 Inhibitor | Pre-clinical Summary | Milestones & highlights
Slide 4: Our Leadership Team
Our Leadership Team MANAGEMENT John Nuss, PhD Jörn Drappa, MD, PhD Raju Mohan, PhD Martin Auster, MD Chris Krueger, JD CHIEF SCIENTIFIC OFFICER CHIEF MEDICAL OFFICER CHIEF EXECUTIVE OFFICER, CHIEF FINANCIAL OFFICER CHIEF BUSINESS OFFICER FOUNDER BOARD OF DIRECTORS Sheila Gujrathi, MD Jigar Choksey R
Slide 5: Our Mission: To become a Leading Immunology Company
Our Mission: To become a Leading Immunology Company Underpinned by Strong Drug Discovery and Development Capabilities WITH THREE, DIFFERENTIATED, CLINICAL-STAGE CANDIDATES and a deep pipeline of preclinical programs that target immune-mediated and inflammatory disease indications OUR INTERNALLY-DISC
Slide 6: Broad Pipeline of Candidates With Multiple Near-Term Catalysts
Broad Pipeline of Candidates With Multiple Near-Term Catalysts Addressing Established Inflammatory and Immunology Markets with a Wholly Owned Product Portfolio TARGET PROGRAM PRECLINICAL PHASE 1 PHASE 2 PHASE 3 NEXT ANTICIPATED MILESTONES Complete Phase 1 MAD H1 2022 TYK2 VTX958 Initiate Phase 2 POC
Slide 7: Pipeline Targeting Large Well-Established Markets
Pipeline Targeting Large Well-Established Markets INDICATION* PATIENTS IN THE U.S. GLOBAL DRUG REVENUE* (2020) TARGET POPULATION Psoriasis 25-30% ~8M ~$20B Dermatology MODERATE-TO-SEVERE Crohn’s disease 30-40% ~700K ~$13B IBD MODERATE-TO-SEVERE Ulcerative colitis 30-40% ~1M ~$7B IBD MODERATE-TO-SEVE
Slide 8: Orally Bioavailable Selective Allosteric Inhibitor of TYK2
ORALLY BIOAVAILABLE selective allosteric inhibitor of TYK2
Slide 9: VTX958 Program Summary
VTX958 Program Summary Allosteric, Selective TYK2 Inhibitor Potentially Differentiated Clinically Validated Target Large Addressable Markets TYK2 Inhibitor • Multiple autoimmune • Selective, allosteric TYK2 inhibitor • Well established clinical efficacy in disorders in dermatology, psoriasis, IBD an
Slide 10: Allosteric Inhibitor VTX958 Binds Selectively to the TYK2 JH2 Domain
Allosteric Inhibitor VTX958 Binds Selectively to the TYK2 JH2 Domain Features of VTX958 IL-12, JH2 Allosteric Inhibition Inhibited Inactive Active IL-23, IFNa Structural Domains in the Selectivity for TYK2 JH2 JAK/TYK2 Family vs. JAK1 JH2 domain (>4,000 X) FERM/SH2 Receptor interaction No binding to
Slide 11: VTX958 More Selective than Deucravacitinib for TYK2 JH2 Domain
VTX958 More Selective than Deucravacitinib for TYK2 JH2 Domain Inhibits TYK2 Pathways (IL-12, IL-23, IFNα) while Avoiding the JAK1/2/3 Pathways DEUCRAVACITINIB VTX958 IL-2, IL-4 IL-10,IL-22 IFNα/β IL-12/23 IFNγ IL-13, IL-15 IL-6 TYK2-JH2 Binding K 0.009 nM 0.058 nM d JAK1-JH2 Binding K 0.43 nM 240 n
Slide 12: VTX958 Selectively Targets IL-12, IL-23 and IFNa
VTX958 Selectively Targets IL-12, IL-23 and IFNa VTX958 Has No Measurable Inhibition VTX958 Potently Inhibits TYK2 Pathways of JAK1-Mediated Pathways Selective and potent inhibition of IL-12/23 and Type I Lack of inhibition of IL-6, IL-10 and other protective interferon axis allows targeting pathway
Slide 13: VTX958 Phase 1 SAD Results Support Clinical Advancement
VTX958 Phase 1 SAD Results Support Clinical Advancement Safety Pharmacokinetics Pharmacodynamics No dose-saturation observed; Dose-dependent VTX958-mediated Well-tolerated across PK and absorption profiles effect on TYK2 signaling observed in all cohorts; all AEs observed suggest continued absorptio
Slide 14: Targeting a Best-in-Class Exposure Profile With VTX958
Targeting a Best-in-Class Exposure Profile With VTX958 Allosteric TYK2 Inhibitors – Target Coverage VTX958 Target Profile • Maximize TYK2 pathway suppression (IC and IC ) 50 90 Deucravacitinib (BMS) 6mg QD NDI-034858 (Nimbus) 30mg QD with once-daily oral dosing • Wide safety margin enabling ~9 hours
Slide 15: VTX958 Profile Expected to Drive Clinical Differentiation
VTX958 Profile Expected to Drive Clinical Differentiation Psoriasis Competitive Landscape Targeting Best-in-Disease Oral Profile with VTX958 KEY TAKEAWAYS 100% 86-91% 76-90% • Current oral options in PsO are substantially less efficacious 80% than biologics VTX 958 • Greater TYK2 suppression may 54-
Slide 16: Unlocking the Opportunity in Crohn's Disease
Unlocking the Opportunity in Crohn’s Disease * Several-fold Higher Doses Required in Crohn’s Agent PsO Dose Crohn’s Dose Greater Exposures Needed for TYK2 Inhibitor Efficacy in Crohn’s 150mg Q12W 600mg IV Q4W (induction) Skyrizi (IL-23) • Biologics data suggest substantially Subcutaneous 360mg SC (m
Slide 17: VTX958 Clinical Development Plan
VTX958 Clinical Development Plan Phase 1 SAD Phase 1 MAD Phase 2 PoC • All 7 cohorts • Explore safety and completed exposure data on Phase 2 PoC Phase 2 trials planned in repeat dosing • Safety and additional indications Initial Phase 2 trial in exposure data allow (psoriatic arthritis, Crohn’s • El
Slide 18: Peripherally Restricted S1P1R Modulator for Ulcerative Colitis
PERIPHERALLY RESTRICTED S1P1R MODULATOR with potential for treatment of ulcerative colitis
Slide 19: VTX002 Program Summary
VTX002 Program Summary Phase 2 S1P1R Modulator for Ulcerative Colitis Potentially Differentiated S1P1R Modulator Clinically Validated Target Large Addressable Markets • Selective S1P1R modulator • S1P1R modulators approved for • Ulcerative colitis is lead MS and UC with clinical trials indication to
Slide 20: VTX002 Differentiates on Multiple Key Parameters vs. Competitors
VTX002 Differentiates on Multiple Key Parameters vs. Competitors Potential for Differentiated Safety Profile No Drug-Drug Interactions Clinical Profile in UC Patients Sustained lymphocyte reduction up to 65% No SAEs, elevated LFTs, abnormal No CYP inhibition; no food effect; favorable across multipl
Slide 21: VTX002 Differentiates on Multiple Key Parameters vs. Competitors
VTX002 Differentiates on Multiple Key Parameters vs. Competitors Differentiating Parameter Ozanimod Etrasimod VTX002 Receptor Selectivity S1P 1,5 S1P 1,4,5 S1P 1,5 Lymphocyte Suppression in Healthy Volunteers 1 mg, ~60% 2 mg, 69% 40 mg, ~65% Lymphocyte Suppression in UC Patients* 1 mg, 49% 2 mg, 40%
Slide 22: Phase 1 MAD Results: Dose-Dependent Exposure and Lymphocyte Reduction
Phase 1 MAD Results: Dose-Dependent Exposure and Lymphocyte Reduction * Absolute Lymphocyte Count (ALC) Reductions of 40-50% Correlated with Clinical Efficacy Observed in UC Pharmacokinetics Pharmacodynamics 0 -20 -40 -60 ****p< 0.0001 **** **** **** **** **** **** **** **** -80 Placebo 2 mg 10 mg 2
Slide 23: Phase 2 Induction Trial in Moderate-to-Severe Ulcerative Colitis
Phase 2 Induction Trial in Moderate-to-Severe Ulcerative Colitis KEY TAKEAWAYS • Powered for primary endpoint of clinical remission • Trial may serve as the first of two pivotal trials required for registration BASELINE WEEK 13* WEEK 52 13-Week Treatment Period 39-Week LTE Treatment Period Screening
Slide 24: Underpenetrated Market for Biologic Refractory Patients
Underpenetrated Market for Biologic Refractory Patients Addressable UC Patient Population in US ~1M UC PATIENTS • Existing agents leave room for new treatments • Novel oral agents may expand 300K+ penetrance of treated moderate-to- MODERATE-TO-SEVERE UC PATIENTS severe UC population beyond current ~
Slide 25: Selective NLRP3 Inflammasome Inhibitors for Systemic and CNS Indications
SELECTIVE NLRP3 INFLAMMASOME INHIBITORS for systemic and CNS indications
Slide 26: Rationale for Targeting the NLRP3 Inflammasome
Rationale for Targeting the NLRP3 Inflammasome NLRP3 Inflammasome Inhibitors Target IL-1b, a Key Driver of Inflammatory Disease Clinical Validation of In vivo Evidence Genetic Evidence Downstream Target • The NLRP3 inflammasome can become • Gain-of-function mutations in the NLRP3 • IL-1β signaling,
Slide 27: NLRP3 Inhibitor Program Summary
NLRP3 Inhibitor Program Summary CNS NLRP3 Inhibitor: VTX3232 Peripheral NLRP3 Inhibitor: VTX2735 • Selective NLRP3 inhibitor • Selective compounds generated with high CNS bioavailability • Well tolerated in GLP safety and tox assessment • Novel and proprietary lead series • Phase 1 ongoing, expected
Slide 28: VTX2735 is a Selective & Orally Bioavailable NLRP3 Inhibitor
VTX2735 is a Selective & Orally Bioavailable NLRP3 Inhibitor Non-Human Primate PK In Vitro Potency & Selectivity Mouse Pharmacodynamic Assay IV Clearance: 1.6 mL/min/kg; Oral Bioavailability: 80% IL-1ß IC (nM) 50 human 2 On monocytes Target human 48 whole blood AIM2 >10000 Off NLRC4 >10000 Target NF
Slide 29: VTX2735 Has Broad Activity Against Multiple NLRP3 Mutations
VTX2735 Has Broad Activity Against Multiple NLRP3 Mutations * Potential for Differentiation in CAPS Setting IC in Blood Monocyte Assay (nM) What is CAPS? 50 An ultra-orphan auto-inflammatory disease caused by various mutations in NLRP3 and 75% MOST characterized by inappropriate of all CAPS patients
Slide 30: CNS-Penetrant NLRP3 Inhibitor VTX3232
CNS-Penetrant NLRP3 Inhibitor VTX3232 KEY TAKEAWAYS • Novel, potent, brain-penetrant inhibitor of NLRP3 • • Unique structural chemotype vs. peripheral NLRP3 inhibitors • Provisional application filed June 2021 • IND filing in Q4 2022; Phase 1 in Q1 2023 T½ = 8 h; Oral Bioavailability = 100% T½ = 4.4
Slide 31: NLRP3 Program Clinical Development Plan
NLRP3 Program Clinical Development Plan Initiate Phase 2 Indication to be Initiate Phase 1 IND-enabling Studies IND approved disclosed Healthy volunteers COMPLETE September 2021 Q4 Q4 2 20 02 21 1 2022 PERIPHERALLY-RESTRICTED IND-Enabling Studies Potential indications include Parkinson’s, Alzheimer’
Slide 32: Our Comprehensive NLRP3 Portfolio Targets a Broad Range of Major Inflammatory Diseases
Our Comprehensive NLRP3 Portfolio Targets a Broad Range of Major Inflammatory Diseases NLRP3 Systemic Diseases Neuroinflammatory Diseases Peripheral NLRP3 inhibitors are CNS-directed NLRP3 inhibitors are designed to treat cardiovascular, designed to treat a range of neuro- rheumatic, fibrotic and ra
Slide 33: Projected Pipeline Catalysts and Summary
PROJECTED PIPELINE CATALYSTS AND SUMMARY 33
Slide 34: Projected Catalysts Over Next Months
Projected Catalysts Over Next 24 Months PROGRAMS H1’2021 H2’2021 H1’2022 H2’2022 2023 Phase 1 SAD Allosteric TYK2 inhibitor addressing a broad Phase 1 MAD Phase 2 in Multiple Indications* range of autoimmune disorders Phase 2 Ulcerative Colitis 13-Week Induction Selective S1P1R modulator targeting U
Slide 35: Investment Highlights
Investment Highlights PRODUCTIVE IMMUNOLOGY PLATFORM • Internal R&D engine designed to generate candidates to address autoimmune and inflammatory diseases with high unmet need • 100% commercial rights to entire portfolio; long patent life for all product candidates POTENTIALLY DIFFERENTIATED MEDICIN
Slide 36: Contact Us for Additional Information
CONTACT US FOR ADDITIONAL INFORMATION: ir@ventyxbio.com VENTYX BIOSCIENCES, INC. 662 ENCINITAS BOULEVARD, SUITE 250 ENCINITAS, CA 92024 36
Ventyx Biosciences — Investor Presentation (March 2022) on 6ix